Xencor (XNCR) Non-Current Assets (2013 - 2026)
Xencor (XNCR) posted quarterly Non-Current Assets of $254.0 million for Q1 2026, down 33.76% year-over-year from $383.4 million in Q1 2025, and down 7.87% quarter-over-quarter from $275.7 million in Q4 2025.
Xencor (XNCR) Non-Current Assets (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Non-Current Assets for 14 consecutive years, with $254.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 33.76% year-over-year to $254.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 13.44% YoY), while the FY2025 annual figure was $275.7 million, down 26.36% from the prior year.
- Non-Current Assets slipped to $254.0 million in Q1 2026 per XNCR's latest filing, from $275.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $410.3 million in Q3 2024 and bottomed at $167.3 million in Q3 2022.
- Historically, Non-Current Assets has averaged $285.8 million across 5 years, with a median of $275.7 million in 2025.
- On a YoY basis, Non-Current Assets climbed as much as 246.52% in 2022 and fell as far as 58.7% in 2022.
- Xencor's Non-Current Assets stood at $170.9 million in 2022, then surged by 92.79% to $329.5 million in 2023, then grew by 13.6% to $374.3 million in 2024, then declined by 26.36% to $275.7 million in 2025, then dropped by 7.87% to $254.0 million in 2026.
- Business Quant data shows XNCR's Non-Current Assets at $254.0 million in Q1 2026, $275.7 million in Q4 2025, and $350.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 201.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 201.75 Mn |
| Mar 31, 2026 | 253.99 Mn |
| Dec 31, 2025 | 275.67 Mn |
| Sep 30, 2025 | 350.37 Mn |
| Jun 30, 2025 | 366.27 Mn |
| Mar 31, 2025 | 383.42 Mn |
| Dec 31, 2024 | 374.34 Mn |
| Sep 30, 2024 | 410.31 Mn |
| Jun 30, 2024 | 271.70 Mn |
| Mar 31, 2024 | 322.00 Mn |
| Dec 31, 2023 | 329.53 Mn |
| Sep 30, 2023 | 207.25 Mn |
| Jun 30, 2023 | 184.56 Mn |
| Mar 31, 2023 | 173.44 Mn |
| Dec 31, 2022 | 170.92 Mn |
| Sep 30, 2022 | 167.27 Mn |
| Jun 30, 2022 | 265.39 Mn |
| Mar 31, 2022 | 351.95 Mn |
| Dec 31, 2021 | 413.84 Mn |
| Sep 30, 2021 | 367.64 Mn |